Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings
Omega Therapeutics, a clinical-stage biotechnology company, announced it will present new preclinical data at three upcoming scientific meetings. The presentations will showcase the company's OMEGA platform and its ability to engineer therapeutic candidates that regulate gene expression with high specificity.
The company will present posters at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, the 12th International mRNA Health Conference, and the American Association for the Study of Liver Diseases' (AASLD) 75th Annual The Liver Meeting®. These presentations will cover topics such as epigenetic upregulation of CXCL9 and CXCL10 in hepatocellular carcinoma, multi-gene tuning of α-globin for thalassemia treatment, and upregulation of HNF4α using epigenomic controllers.
Omega Therapeutics (Nasdaq: OMGA) is developing programmable epigenomic mRNA medicines to treat or cure a broad range of diseases by modulating gene expression without altering native nucleic acid sequences.
Omega Therapeutics, un'azienda biotecnologica in fase clinica, ha annunciato che presenterà nuovi dati preclinici in tre prossimi incontri scientifici. Le presentazioni metteranno in evidenza la piattaforma OMEGA dell'azienda e la sua capacità di ingegnerizzare candidati terapeutici che regolano l'espressione genica con alta specificità.
L'azienda presenterà poster al 39° Convegno Annuale della Society for Immunotherapy of Cancer (SITC), al 12° Convegno Internazionale sulla Salute mRNA, e al 75° Convegno Annuale The Liver Meeting® dell'American Association for the Study of Liver Diseases (AASLD). Queste presentazioni tratteranno argomenti come l'upregulation epigenetica di CXCL9 e CXCL10 nel carcinoma epatocellulare, la regolazione di più geni dell'α-globina per il trattamento della talassemia, e l'upregulation di HNF4α utilizzando controllori epigenomici.
Omega Therapeutics (Nasdaq: OMGA) sta sviluppando medicine mRNA epigenomiche programmabili per trattare o curare una vasta gamma di malattie modulando l'espressione genica senza alterare le sequenze di acidi nucleici native.
Omega Therapeutics, una empresa biotecnológica en etapa clínica, anunció que presentará nuevos datos preclínicos en tres próximos encuentros científicos. Las presentaciones mostrarán la plataforma OMEGA de la empresa y su capacidad para diseñar candidatos terapéuticos que regulen la expresión génica con alta especificidad.
La empresa presentará carteles en el 39° Encuentro Anual de la Society for Immunotherapy of Cancer (SITC), en la 12° Conferencia Internacional sobre Salud del mRNA, y en el 75° Encuentro Anual The Liver Meeting® de la American Association for the Study of Liver Diseases (AASLD). Estas presentaciones cubrirán temas como la regulación epigenética de CXCL9 y CXCL10 en el carcinoma hepatocelular, la afinación multigénica de α-globina para el tratamiento de la talasemia, y la regulación al alza de HNF4α utilizando controladores epigenómicos.
Omega Therapeutics (Nasdaq: OMGA) está desarrollando medicamentos de mRNA epigenómico programables para tratar o curar una amplia gama de enfermedades modulando la expresión génica sin alterar las secuencias de ácidos nucleicos nativos.
임상 단계의 생명공학 회사인 오메가 테라퓨틱스는 세 가지 다가오는 과학 회의에서 새로운 전임상 데이터를 발표할 것이라고 발표했습니다. 발표는 회사의 OMEGA 플랫폼과 유전자 발현을 높은 특이성으로 조절하는 치료 후보를 설계하는 능력을 보여줄 것입니다.
회사는 암 면역요법 학회의 제39회 연례 회의(SITC), 제12회 국제 mRNA 건강 회의, 및 간 질환 연구 미국 협회(AASLD)의 제75회 연례 The Liver Meeting®에서 포스터를 발표할 것입니다. 이러한 발표는 간세포암에서의 CXCL9 및 CXCL10의 후생유전학적 상향 조정, 탈라세미아 치료를 위한 α-글로빈의 다유전자 조정, 후생유전체 조절기를 사용한 HNF4α의 상향 조정과 같은 주제를 다룰 것입니다.
오메가 테라퓨틱스(Nasdaq: OMGA)는 본래의 핵산 서열을 변경하지 않고 유전자 발현을 조절하여 광범위한 질병을 치료하거나 치유하기 위한 프로그래머블 후생유전체 mRNA 의약품을 개발하고 있습니다.
Omega Therapeutics, une entreprise de biotechnologie en phase clinique, a annoncé qu'elle présentera de nouvelles données précliniques lors de trois prochaines réunions scientifiques. Les présentations mettront en avant la plateforme OMEGA de l'entreprise et sa capacité à concevoir des candidats thérapeutiques qui régulent l'expression des gènes avec une haute spécificité.
L'entreprise présentera des affiches lors de la 39e Réunion Annuelle de la Society for Immunotherapy of Cancer (SITC), de la 12e Conférence Internationale sur la Santé mRNA et de la 75e Réunion Annuelle The Liver Meeting® de l'American Association for the Study of Liver Diseases (AASLD). Ces présentations aborderont des sujets tels que la régulation épigénétique de CXCL9 et CXCL10 dans le carcinome hépatocellulaire, le réglage multi-gène de l'α-globine pour le traitement de la thalassémie, et la régulation à la hausse de HNF4α à l'aide de contrôleurs épigénomiques.
Omega Therapeutics (Nasdaq: OMGA) développe des médicaments en mRNA épigénomiques programmables pour traiter ou guérir un large éventail de maladies en modulant l'expression génique sans altérer les séquences d'acides nucléiques native.
Omega Therapeutics, ein biopharmazeutisches Unternehmen in der klinischen Phase, hat angekündigt, dass es neue präklinische Daten auf drei bevorstehenden wissenschaftlichen Tagungen präsentieren wird. Die Präsentationen werden die OMEGA-Plattform des Unternehmens und ihre Fähigkeit zur Entwicklung von therapeutischen Kandidaten, die die Genexpression mit hoher Spezifität regulieren, hervorheben.
Das Unternehmen wird Poster auf dem 39. Jahresmeeting der Society for Immunotherapy of Cancer (SITC), der 12. International mRNA Health Conference und dem 75. Annual The Liver Meeting® der American Association for the Study of Liver Diseases (AASLD) präsentieren. Diese Präsentationen behandeln Themen wie die epigenetische Hochregulation von CXCL9 und CXCL10 bei hepatozellulärem Karzinom, die Multigen-Tuning von α-Globin zur Behandlung von Thalassämie und die Hochregulation von HNF4α unter Verwendung von epigenomischen Steuerungen.
Omega Therapeutics (Nasdaq: OMGA) entwickelt programmierbare epigenomische mRNA-Medikamente zur Behandlung oder Heilung einer Vielzahl von Krankheiten, indem sie die Genexpression modulieren, ohne die nativen Nukleinsäuresequenzen zu verändern.
- None.
- None.
CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced it will share new preclinical data at three upcoming scientific meetings.
“These preclinical results build upon the foundation of data we have shared to date and expand our confidence in the ability of epigenomic controllers to upregulate or downregulate the expression of one or more genes,” said Mahesh Karande, President and Chief Executive Officer of Omega Therapeutics. “More broadly, we believe these upcoming presentations further demonstrate the power of the OMEGA platform to prospectively engineer novel therapeutic candidates to regulate gene expression with high specificity and the potential of precision epigenomic control to offer new treatment strategies for diverse indications.”
Details for the upcoming presentations are as follows:
Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting taking place in Houston, TX, November 8 – 10
Title: Controlled Epigenetic Upregulation of CXCL9 and CXCL10 in Hepatocellular Carcinoma Promotes T-cell Recruitment
Abstract Number: 1360
Session Date and Time: Saturday, November 9, 2024, from 12:15 to 1:45 p.m. CST
Poster and Flash Talk at the 12th International mRNA Health Conference taking place in Boston, MA, November 12 – 14
Title: Programmable Epigenomic mRNA Therapeutics Enable Multi-Gene Up or Down Tuning of α-globin via Regulatory Element Targeting: A Precision Approach for β- and α-Thalassemia Treatment
Paper Number: 102
E-Poster Session Date and Time: Tuesday, November 12, 2024, beginning at 9:00 a.m. EST
Flash Talk Session Date and Time: Tuesday, November 12, 2024, from 4:00 to 5:00 p.m. EST
Poster at the American Association for the Study of Liver Diseases’ (AASLD) 75th Annual The Liver Meeting® taking place in San Diego, CA, November 15 – 19
Title: Durable Upregulation of P1-isoform Hepatocyte Nuclear Factor 4 alpha (HNF4α) Using Novel Epigenomic Controllers
Publication Number: 3228
Session Title: MASLD/MASH - Therapeutics: New Agents
Session Date and Time: Sunday, November 17, 2024, from 8:00 a.m. to 5 p.m. PST
The posters will be made available on the Omega website at https://omegatherapeutics.com/science/publications/ at the same time as the respective presentations.
About Omega Therapeutics
Omega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines to treat or cure a broad range of diseases. By pre-transcriptionally modulating gene expression, Omega’s approach enables precision epigenomic control of nearly all human genes, including historically undruggable and difficult-to-treat targets, without altering native nucleic acid sequences. Founded in 2017 by Flagship Pioneering following breakthrough research by world-renowned experts in the field of epigenetics, Omega is led by a seasoned and accomplished leadership team with a track record of innovation and operational excellence. The Company is committed to revolutionizing genomic medicine and has a pipeline of therapeutic candidates derived from its OMEGA platform spanning oncology, regenerative medicine, and multigenic diseases including inflammatory and cardiometabolic conditions.
For more information, visit omegatherapeutics.com, or follow us on X and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding our expectations surrounding the broad potential of precision epigenomic control, the versatile capabilities of the OMEGA platform, the potential of the Company’s pipeline of therapeutic candidates, and the Company’s participation in upcoming events and presentations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the novel technology on which our product candidates are based makes it difficult to predict the time and cost of preclinical and clinical development and subsequently obtaining regulatory approval, if at all; the substantial development and regulatory risks associated with epigenomic controllers due to the novel and unprecedented nature of this new category of medicines; our limited operating history; the incurrence of significant losses and the fact that we expect to continue to incur significant additional losses for the foreseeable future; our need for substantial additional financing; volatility in capital markets and general economic conditions; our investments in research and development efforts that further enhance the OMEGA platform, and their impact on our results; uncertainty regarding preclinical development, especially for a new class of medicines such as epigenomic controllers; potential delays in and unforeseen costs arising from our clinical trials; the fact that our product candidates may be associated with serious adverse events, undesirable side effects or have other properties that could halt their regulatory development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences; difficulties manufacturing the novel technology on which our epigenomic controller candidates are based; our ability to adapt to rapid and significant technological change; our reliance on third parties for the manufacture of materials; our ability to successfully acquire and establish our own manufacturing facilities and infrastructure; our reliance on a limited number of suppliers for lipid excipients used in our product candidates; our ability to advance our product candidates to clinical development; and our ability to obtain, maintain, enforce and adequately protect our intellectual property rights. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, and our other filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
FAQ
What scientific meetings will Omega Therapeutics (OMGA) present at in November 2024?
What is the focus of Omega Therapeutics' (OMGA) poster at the SITC Annual Meeting?
What will Omega Therapeutics (OMGA) present at the International mRNA Health Conference?
What is the topic of Omega Therapeutics' (OMGA) poster at The Liver Meeting 2024?
When will Omega Therapeutics (OMGA) make the posters available on their website?
